KD Logo

Cyclacel Pharmaceuticals Inc [CYCC] Investment Guide: What You Need to Know

Cyclacel Pharmaceuticals Inc’s recently made public that its President and CEO Rombotis Spiro George acquired Company’s shares for reported $20122.0 on Dec 21 ’23. In the deal valued at $3.31 per share,6,070 shares were bought. As a result of this transaction, Rombotis Spiro George now holds 68,658 shares worth roughly $0.19 million.

Then, McBarron Paul bought 1,886 shares, generating $6,252 in total proceeds. Upon buying the shares at $3.31, the insider now owns 33,378 shares.

Ladenburg Thalmann began covering CYCC with “Buy” recommendation on September 07, 2018. H.C. Wainwright started covering the stock on October 16, 2015. It rated CYCC as “a Buy”.

Price Performance Review of CYCC

On Tuesday, Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] saw its stock jump 11.81% to $2.84. Over the last five days, the stock has gained 34.60%. Cyclacel Pharmaceuticals Inc shares have risen nearly 6.37% since the year began. Nevertheless, the stocks have fallen -65.60% over the past one year. While a 52-week high of $13.20 was reached on 05/01/24, a 52-week low of $1.30 was recorded on 04/29/24. SMA at 50 days reached $2.15, while 200 days put it at $4.36. A total of 0.26 million shares were traded, compared to the trading of 0.39 million shares in the previous session.

Levels Of Support And Resistance For CYCC Stock

The 24-hour chart illustrates a support level at 2.43, which if violated will result in even more drops to 2.01. On the upside, there is a resistance level at 3.05. A further resistance level may holdings at 3.25. The Relative Strength Index (RSI) on the 14-day chart is 62.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 42.96%. Stochastics %K at 46.30% indicates the stock is a holding.

The most recent change occurred on February 04, 2010 when Roth Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.

Most Popular

[the_ad id="945"]